Biogen

Yahoo Finance • 16 hours ago

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling... Full story

Yahoo Finance • 2 days ago

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improveme... Full story

Yahoo Finance • 4 days ago

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes

AUSTIN, Texas and TOKYO, Oct. 7, 2025 /PRNewswire/ -- The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene therapy, antisense oligonucleotides (ASOs), monoclonal antib... Full story

Yahoo Finance • 5 days ago

Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenanc... Full story

Yahoo Finance • 5 days ago

Biogen Leqembi at-home maintenance dose for Alzheimer's available

[Alzheimers Concept Horizontal] travellinglight/iStock via Getty Images * Eisai (OTCPK:ESALF [https://seekingalpha.com/symbol/ESALF]) and Biogen (NASDAQ:BIIB [https://seekingalpha.com/symbol/BIIB]) have launched Leqembi IQLIK, a subcuta... Full story

Yahoo Finance • 5 days ago

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and more LEQEMBI... Full story

Yahoo Finance • 5 days ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Plug Power Inc. 155,000,553 4.58 3.85 3.8888 +0.0788 Advanced Micro Devi... Full story

Yahoo Finance • 5 days ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 6 days ago

Notable healthcare headlines for the week: Pfizer, Novo Nordisk and JNJ in focus

Wall Street’s broader market averages closed mixed on Friday as market participants digested the U.S. government shutdown for the third day. For the week, the Dow, S&P 500, and Nasdaq Composite advanced by 1.1%, 1.08%, and 1.32%, respecti... Full story

Yahoo Finance • 9 days ago

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 9 days ago

Stocks Rise Before the Open on Fed Rate-Cut Hopes and AI Optimism

December S&P 500 E-Mini futures (ESZ25 [https://www.barchart.com/futures/quotes/ESZ25]) are up +0.14%, and December Nasdaq 100 E-Mini futures (NQZ25 [https://www.barchart.com/futures/quotes/NQZ25/overview]) are up +0.32% this morning, buoy... Full story

Yahoo Finance • 10 days ago

Drug Stock Rally Helps Push Dow and S&P 500 to Records

Pharma stocks climbed for a second session, extending gains that began after President Trump unveiled a direct-to-consumer website for Americans to buy drugs. Amgen and Merck both climbed more than 5%, to push the Dow Jones Industrial Aver... Full story

Yahoo Finance • 10 days ago

Stocks Rally as Weak US Jobs News Reinforces Fed Rate Cut Hopes

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Wednesday closed up +0.34%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.co... Full story

Yahoo Finance • 10 days ago

Stocks Trim Losses as Drug Makers Rally

The S&P 500 Index ($SPX) (SPY) today is down -0.08%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.06%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.02%.  December E-mini S&P futures (ESZ25) are down -0.05%, and December E-mi... Full story

Yahoo Finance • 13 days ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China

TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbach... Full story

Yahoo Finance • 13 days ago

Biogen Inc. (BIIB): A Bull Case Theory

We came across a bullish thesis on Biogen Inc. on Investing With Purpose’s Substack. In this article, we will summarize the bulls’ thesis on BIIB. Biogen Inc.'s share was trading at $143.81 as of September 18th. BIIB’s trailing and forwar... Full story

Yahoo Finance • 16 days ago

Oracle initiated, Ulta Beauty upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Argus upgraded Ulta Beauty(ULTA) to Bu... Full story

Yahoo Finance • 17 days ago

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbach... Full story

Yahoo Finance • 18 days ago

Biogen gets complete response letter from FDA for higher dose Spinraza

[Neuron system disease] koto_feja/E+ via Getty Images Biogen (NASDAQ:BIIB [https://seekingalpha.com/symbol/BIIB]) reported that the U.S. FDA has declined to accept its request for a supplemental marketing authorization for a higher dose o... Full story

Yahoo Finance • 18 days ago

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application... Full story